Covid-19 vaccine trial by Moderna shows promising early results
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Sunday
July 03, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SUNDAY, JULY 03, 2022
Covid-19 vaccine trial by Moderna shows promising early results

Coronavirus chronicle

TBS Report
18 May, 2020, 07:35 pm
Last modified: 18 May, 2020, 08:36 pm

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit
  • Britain approves Valneva's easy-to-store Covid shot
  • More funds incoming from dev partners for vaccine purchase

Covid-19 vaccine trial by Moderna shows promising early results

The company has said that it is proceeding on an accelerated timetable, with the second phase involving 600 people to begin soon, and a third phase to begin in July

TBS Report
18 May, 2020, 07:35 pm
Last modified: 18 May, 2020, 08:36 pm
File Photo: A woman holds a small bottle labeled with a "Vaccine Covid-19" sticker and a medical syringe in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration
File Photo: A woman holds a small bottle labeled with a "Vaccine Covid-19" sticker and a medical syringe in this illustration taken April 10, 2020. Reuters/Dado Ruvic/Illustration

The first coronavirus vaccine to be tested in people appears to be safe and able to stimulate an immune response against the virus, its manufacturer, Moderna announced on Monday.

The findings are based on results from the first eight people who each received two doses of the vaccine, starting in March, reports the New York Times.

Those people, healthy volunteers, made antibodies that were then tested in human cells in the lab, and were able to stop the virus from replicating — the key requirement for an effective vaccine. The levels of those so-called neutralizing antibodies matched the levels found in patients who had recovered after contracting the virus in the community.

The company has said that it is proceeding on an accelerated timetable, with the second phase involving 600 people to begin soon, and a third phase to begin in July involving thousands of healthy people. The US Food and Drug Administration gave Moderna the go-ahead for the second phase earlier this month.

If those trials go well, a vaccine could become available for widespread use by the end of this year or early 2021, Dr Tal Zaks, Moderna's chief medical officer, said in an interview. How many doses might be ready is not clear, but Dr Zaks said, "We're doing our best to make it as many millions as possible."

There is no proven treatment or vaccine against the coronavirus at this time. Dozens of companies in the United States, Europe and China are racing to produce vaccines, using different methods. Some use the same technology as Moderna, which involves a segment of genetic material from the virus called messenger RNA, or mRNA.

Moderna said that additional tests in mice that were vaccinated and then infected found that the vaccine could prevent the virus from replicating in their lungs, and that the animals had levels of neutralizing antibodies comparable to those in the people who had received the vaccine.

Three doses of the vaccine were tested: low, medium and high. These initial results are based on tests of the low and medium doses. The only adverse effect at those doses was redness and soreness in one patient's arm where the shot was given.

But at the highest dose, three patients had fever, muscles and headaches, Dr Zaks said, adding that the symptoms went away after a day.

But the high dose is being eliminated from future studies, not so much because of the side effects, but because the lower doses appeared to work so well that the high dose is not needed.

"The lower the dose, the more vaccine we'll be able to make," Dr Zaks said.

Moderna's stock was up 40 percent in pre-market trading.

Top News

Coronavirus Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Photo of Bangladesh Secretariat/Collected
    Govt stops purchasing new cars for ministries, departments
  • Photo :Noor-A-Alam
    SSC exams to be held in August
  • No more honorarium for government meetings
    No more honorarium for government meetings

MOST VIEWED

  • A man helps his son to wear mask at Covid-19 test centre at KSRTC bus stand in Bengaluru.(PTI)
    India records 16,103 new Covid cases, 31 deaths in 24 hours
  • Former North Korean defectors living in South Korea, release balloons containing one dollar banknotes, radios, CDs and leaflets denouncing the North Korean regime, towards the north near the demilitarized zone which separates the two Koreas in Paju, north of Seoul January 15, 2014. REUTERS/Kim Hong-Ji/File Photo
    North Korea blames 'alien things' near border with South for Covid outbreak
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
    BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    S Korea approves first domestically developed Covid vaccine
  • Photo: Collected
    US medical experts call for Omicron-specific Covid boosters

Related News

  • Pfizer says 3 Covid shots protect children under 5
  • Covax calls for urgent action to close vaccine equity gap
  • US to share Covid vaccine technology, Biden tells global summit
  • Britain approves Valneva's easy-to-store Covid shot
  • More funds incoming from dev partners for vaccine purchase

Features

A Glittery Eid

A Glittery Eid

4h | Mode
Rise’s target customers are people who crave to express themselves through what they wear, and their clothing line is not relegated to any age range.

Level up your Eid game with Rise

4h | Mode
Stefan Dercon, a Professor of Economics at the University of Oxford and former Chief Economist of the Department of International Development (DFID). Illustration: TBS

Renewing the ‘elite bargain’ for Bangladesh’s future growth

7h | Panorama
The eye-catching commuter: Suzuki Gixxer SF 155

The eye-catching commuter: Suzuki Gixxer SF 155

1d | Wheels

More Videos from TBS

Chirkutt performs on Fete de La Music Fest

Chirkutt performs on Fete de La Music Fest

6h | Videos
Madhuri Sanchita's seed ornaments exhibition

Madhuri Sanchita's seed ornaments exhibition

6h | Videos
Bangabandhu Tunnel to change lives of million

Bangabandhu Tunnel to change lives of million

18h | Videos
Sowari Ghat's fresh fish market

Sowari Ghat's fresh fish market

18h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
TBS Illustration
Education

Universities may launch online classes again after Eid

4
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

5
Photo: Collected
Economy

Tech startup ShopUp bags $65m in Series B4 funding

6
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
Launch operators on various river routes see a steep drop in passengers after the opening of the the Padma Bridge. Photo: TBS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net